CheckMyRecalls

Lupin Pharmaceuticals Inc. recalls Ganirelix Acetate Injection

Published
17 Dec 2025
Units affected
32736 vials
Agency
FDA
Country
United States

The hazard

Failed impurities/degradation specifications: out of specification results for Ganirelix acetate acrylic acid adduct impurity.

Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.

What to do

Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.

  • Check the lot number on the box or bottle.
  • Talk to your pharmacist or doctor before stopping any prescribed medicine.
  • Return the product to the pharmacy for safe disposal.
Read the official FDA notice

Product details

Ganirelix Acetate Injection, 250 mcg/0.5mL, Single-dose Sterile Prefilled Syringe, 27 gauge by 1/2' needle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Naples, FL 34108, United States, Manufactured by: Lupin Limited, Nagpur - 441108, INDIA, NDC 70748-274-01

Brand / company
Lupin Pharmaceuticals Inc.
Codes / lots
Lot #: WB00006, Exp 12/31/2026
Distribution
FL, MA, MI & OH
Recall status
Ongoing

Source: U.S. Food and Drug Administration, published 17 Dec 2025. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.